Beginning in 1992, the Agency for Health Care Policy and Research and the National Institute of Mental Health funded the Schizophrenia Patient Outcomes Research Team (PORT) to develop and disseminate recommendations for the treatment of schizophrenia based on existing scientific evidence. These Treatment Recommendations, presented here in final form for the first time, are based on exhaustive reviews of the treatment outcomes literature (previously published in Schizophrenia Bulletin, Vol. 21, No. 4, 1995) and focus on those treatments for which there is substantial evidence of efficacy. The recommendations address antipsychotic agents, adjunctive pharmacotherapies, electroconvulsive therapy, psychological interventions, family interventions, vocational rehabilitation, and assertive community treatment/intensive case management. Support for each recommendation is referenced to the previous PORT literature reviews, and the recommendations are rated according to the level of supporting evidence. The PORT Treatment Recommendations provide a basis for moving toward “evidence-based” practice for schizophrenia and identify both the strengths and limitations in our current knowledge base.
Baldessarini, R.J.; Cohen, B.M.; and Teicher, M.
Pharmacologic treatment In: Levy, S.T., and Ninan, P.T.,
eds. Schizophrenia: Treatment of Acute Psychotic
Episodes. Washington DC: American Psychiatric Press,
1990. pp. 61-118.
Buchanan, R.W. Clozapine: Efficacy and safety.
Schizophrenia Bulletin, 21(4):579-591,1995.
Davis, J.M.; Barter, J.T.; and Kane, J.M. Antipsychotic
drugs. In: Kaplan, H.I., and Sadock, B.J., eds.
Comprehensive Textbook of Psychiatry. Baltimore, MD:
Williams & Wilkins, 1989. pp. 1591-1626.
Dixon, L.B., and Lehman, A.F. Family interventions for
schizophrenia. Schizophrenia Bulletin, 21(4):631-643,
Dixon, L.B.; Lehman, A.F.; and Levine, J. Conventional
antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 21(4):567-577, 1995.
Johns, C.A., and Thompson, J.W. Adjunctive treatments
in schizophrenia: Pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin, 21(4):607-619,
Kane, J.M. Schizophrenia. New England Journal of
Medicine, 334:34-41, 1996.
Kane, J.M., and Marder, S.R. Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19(2):
Kissling, W. Ideal and reality of neuroleptic relapse
prevention. British Journal of Psychiatry, 161
(Suppl.): 133-139, 1992.
Lehman, A.F. Vocational rehabilitation in schizophrenia.
Schizophrenia Bulletin, 21(4):645-656, 1995.
Rifkin, A., and Siris, S. Drug treatment of acute schizophrenia. In: Meltzer, H., ed. Psychopharmacology: The
Third Generation of Progress. New York, NY: Raven
Press, 1987. pp. 1095-1101.
Scott, J.E., and Dixon, L.B. Assertive community treatment and case management for schizophrenia.
Schizophrenia Bulletin, 21(4):657-668,1995a.
Scott, J.E., and Dixon, L.B. Psychological interventions
for schizophrenia. Schizophrenia Bulletin, 21(4):621-630,
Umbricht, D., and Kane, J.M. Risperidone: Efficacy and
safety. Schizophrenia Bulletin, 21(4):593-606, 1995.
Zito, J.M. Psychotherapeutic Drug Manual. 3rd ed. New
York, NY: John Wiley & Sons, 1994.
Go to 'Translating Research Into Practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations'
Contributed on 12/4/2012
Type of Resource